Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
The U.S. Department of Education said Tuesday itβs developed six agreements to send many of its key functions to other federal agencies. A majority of the Education Departmentβs funding for K-12 ...
αΆαα΅ α³αα«α«α αα αα°αα? αα
α₯α«α α¨34 ααα³α΅ α ααα α΅αααα ααα΅ α αααΆ ααα½ α αα°α°α α α΅αα’ α°ααααΉ ααα‘α ααα³αα€ α αα©α ααα³α ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
The best laptops for coding and programming will feature the latest hardware and be capable of being pushed to the limits. You'll ideally be able to work across multiple programs at once, thanks to a ...
RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, Iβm not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybioβs entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
β Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million β β Extends Rallybio Cash Runway to Mid-2027 β The REV102 program originated from a joint venture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback